Christopher D.�M. Fletcher
YOU?
Author Swipe
View article: Genetic correlates of malignancy in <scp><i>TFE3</i></scp>‐rearranged <scp>PEComa</scp>: a series of 14 cases
Genetic correlates of malignancy in <span><i>TFE3</i></span>‐rearranged <span>PEComa</span>: a series of 14 cases Open
Aims Perivascular epithelioid cell tumours (PEComas) show variable smooth muscle and melanocytic differentiation and mostly harbour mTOR pathway activation via TSC2 inactivation. Five–10% of sporadic PEComas instead harbour fusions involvi…
View article: <scp>MicroRNA</scp>‐371–373 cluster and methylome analysis suggests that a subset of ‘somatic‐type’ malignancies arising in germ cell tumors may originate in yolk sac tumor components
<span>MicroRNA</span>‐371–373 cluster and methylome analysis suggests that a subset of ‘somatic‐type’ malignancies arising in germ cell tumors may originate in yolk sac tumor components Open
Somatic‐type malignancies (SMs) arising in germ cell tumors (GCTs) are aggressive neoplasms resistant to systemic treatment. Most are diagnosed in metastatic sites after chemotherapy; however, they have also been well‐documented in primary…
View article: International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms
International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms Open
The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS, SEF, or H-LGFM…
View article: Characterizing and Optimizing Real-Time Optimal Control for Embedded SoCs
Characterizing and Optimizing Real-Time Optimal Control for Embedded SoCs Open
Resource-limited robots face significant challenges in executing computationally intensive tasks, such as locomotion and manipulation, particularly for real-time optimal control algorithms like Model Predictive Control (MPC). This paper pr…
View article: A Comparative Genomic Study of Conventional and Undifferentiated Melanoma
A Comparative Genomic Study of Conventional and Undifferentiated Melanoma Open
View article: Activation induces shift in nutrient utilization that differentially impacts cell functions in human neutrophils
Activation induces shift in nutrient utilization that differentially impacts cell functions in human neutrophils Open
Neutrophils utilize a variety of metabolic sources to support their crucial functions as the first responders in innate immunity. Here, through in vivo and ex vivo isotopic tracing, we examined the contributions of different nutrients to n…
View article: Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group Open
View article: Integration of a clinical pharmacist practitioner–led pharmacogenomics service in a Veterans Affairs hematology/oncology clinic
Integration of a clinical pharmacist practitioner–led pharmacogenomics service in a Veterans Affairs hematology/oncology clinic Open
Purpose This article describes the implementation and evaluation of pharmacogenomic testing within the hematology/oncology ambulatory care clinic at the William S. Middleton Memorial Veterans Hospital in Madison, WI. Summary The Pharmacoge…
View article: Combining Obinutuzumab With Radiation for Refractory DLBCL: Retrospective Safety and Efficacy Analysis
Combining Obinutuzumab With Radiation for Refractory DLBCL: Retrospective Safety and Efficacy Analysis Open
In this small cohort of treatment-refractory patients with DLBCL, the combination of radiation and obinutuzumab was well tolerated without excessive treatment-related toxicity. The combination resulted in durable disease control with a pro…
View article: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024 Open
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications h…
View article: Activation induces shift in nutrient utilization that differentially impacts cell functions in human neutrophils
Activation induces shift in nutrient utilization that differentially impacts cell functions in human neutrophils Open
Neutrophils – the first responders in innate immunity – perform a variety of effector functions associated with specific metabolic demand. To maintain fitness and support functions, neutrophils have been found to utilize extracellular gluc…
View article: Papillary Hemangioma Harbors Somatic GNA11 and GNAQ Mutations
Papillary Hemangioma Harbors Somatic GNA11 and GNAQ Mutations Open
Papillary hemangioma (PH) is a small, primarily dermal lesion occurring predominantly in the head and neck in both children and adults. Its signature characteristics are dilated thin-walled channels containing papillary clusters of mainly …
View article: Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI)
Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI) Open
Background: Recent studies demonstrated that classical Hodgkin lymphoma (cHL) is characterized by chromosome 9p24.1 amplification with associated overexpression of PD-1 ligands and JAK2 tyrosine kinase activation. JAK2 signaling augments t…
View article: Supplementary Figure S1 from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Supplementary Figure S1 from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma Open
Supplementary Figure S1. qRT-PCR results for PRDM10
View article: Data from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Data from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma Open
Purpose: Undifferentiated pleomorphic sarcoma (UPS) is defined as a sarcoma with cellular pleomorphism and no identifiable line of differentiation. It is typically a high-grade lesion with a metastatic rate of about one third. No tu…
View article: Data from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Data from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
Purpose: Programmed cell death ligand 1 (PD-L1) is an immunomodulatory molecule expressed by antigen-presenting cells and select tumors that engages receptors on T cells to inhibit T-cell immunity. Immunotherapies targeting the PD-1…
View article: Data from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Data from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
Purpose: Programmed cell death ligand 1 (PD-L1) is an immunomodulatory molecule expressed by antigen-presenting cells and select tumors that engages receptors on T cells to inhibit T-cell immunity. Immunotherapies targeting the PD-1…
View article: Supplementary Figure 1 Legend from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Supplementary Figure 1 Legend from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma Open
Supplementary Figure 1 Legend.
View article: Supplementary Table 1 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Supplementary Table 1 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
PDF file - 75K, Supplemental Table 1. Pathological Characteristics and PD-L1 Expression in Hodgkin Lymphomas and Related Cases.
View article: Data from Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
Data from Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure Open
Purpose: To evaluate sunitinib activity and potential cellular and molecular correlates in gastrointestinal stromal tumor (GIST) patients after imatinib failure, in addition to assessing the safety and pharmacokinetics (PK) of diffe…
View article: Supplementary Tables S1-S9 from Clinically Relevant Molecular Subtypes in Leiomyosarcoma
Supplementary Tables S1-S9 from Clinically Relevant Molecular Subtypes in Leiomyosarcoma Open
Supplementary Tables S1-S9. Table S1: Clinicopathological characterization of 99 Leiomyosarcoma cases; Table S2: Patient clinical features for TCGA dataset (N=82); Table S3: The number of overlapping genes by SAMSeq analysis between 3SEQ a…
View article: Supplementary Table 2 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Supplementary Table 2 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
PDF file - 80K, Supplemental Table 2. Pathological Characteristics and PD-L1 Expression in Non-Hodgkin Lymphoma Cases.
View article: Supplementary Figure 1 Legend from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Supplementary Figure 1 Legend from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma Open
Supplementary Figure 1 Legend.
View article: Supplementary Table S1 from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Supplementary Table S1 from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma Open
Supplementary Table S1. Clinical, morphologic, and genetic data on the patient cohort
View article: Supplementary Table S2 from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Supplementary Table S2 from Recurrent <i>PRDM10</i> Gene Fusions in Undifferentiated Pleomorphic Sarcoma Open
Supplementary Table S2. Primers used for RT-PCR and sequencing
View article: Supplementary Figure Legend from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Supplementary Figure Legend from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
PDF file - 48K
View article: Supplementary Figure Legend from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Supplementary Figure Legend from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
PDF file - 48K
View article: Supplementary Methods from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Supplementary Methods from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
PDF file - 56K
View article: Supplementary Table 2 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Supplementary Table 2 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
PDF file - 80K, Supplemental Table 2. Pathological Characteristics and PD-L1 Expression in Non-Hodgkin Lymphoma Cases.
View article: Supplementary Table 3 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Supplementary Table 3 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Open
PDF file - 69K, Supplemental Table 3. Correlative Expression of PD-L1 by Malignant Cells and the Cellular Microenvironment of Examined Tumor Types.